POTASSIUM PHOSPHATES INJECTION, USP
(3 mmol Phosphorus/mL and 4.4 mmol Potassium/mL 4.4 mEq Potassium/mL)
7.4 mOsmol/mL
pH 6.2 – 6.8
For IV Infusion After Dilution

DESCRIPTION

Potassium Phosphates Injection, USP is a sterile, nonpyrogenic, concentrated solution containing a mixture of mono- and dibasic potassium phosphate in Water for Injection. It must be diluted prior to administration.

Each mL of the solution consists of two phosphate salts provided as follows:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Phosphate</th>
<th>Potassium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monobasic Potassium Phosphate – 224 mg</td>
<td>285 mg</td>
<td>170 mg</td>
</tr>
<tr>
<td>Dibasic Potassium Phosphate – 236 mg</td>
<td>(3 mmol)</td>
<td>(4.4 mEq)</td>
</tr>
</tbody>
</table>

The solution contains no bacteriostatic agent or other preservative.

The solution is intended to provide phosphate ion (PO$_4$$^{3-}$) for addition to large volume infusion fluids for intravenous use. Unused portions should be discarded.

CLINICAL PHARMACOLOGY

Phosphorus in the form of organic and inorganic phosphate has a variety of important biochemical functions in the body and is involved in many significant metabolic and enzyme reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium and a primary role in the renal excretion of hydrogen ion.

Phosphorus is present in plasma and other extracellular fluid, in cell membranes and intracellular fluid, as well as in collagen and bone tissues. Phosphate in the extracellular fluid is primarily in inorganic form, and plasma levels may vary somewhat with age. The ratio of disodium phosphate and monosodium phosphate in the extracellular fluid is 4:1 (80%:20%) at the normal pH of 7.4. This buffer ratio varies with the pH, but owing to its relatively low concentration, it contributes little to the buffering capacity of the extracellular fluids.
Phosphate, present in large amounts in erythrocytes and other tissue cells, plays a significant intracellular role in the synthesis of high energy organic phosphates.

Hypophosphatemia should be avoided during periods of total parenteral nutrition, or other lengthy periods of intravenous infusions. Serum phosphate levels should be regularly monitored, and appropriate amounts of phosphate should be added to the infusions to maintain normal serum phosphate levels. Intravenous infusion of inorganic phosphate may be accompanied by a decrease in the serum level and urinary excretion of calcium. Intravenously infused phosphate not taken up by the tissues is excreted almost entirely in the urine.

**INDICATIONS AND USAGE**

Potassium Phosphates Injection, USP (3 mmol/mL), is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

**CONTRAINDICATIONS**

Potassium Phosphates Injection, USP is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.

**WARNINGS**

Potassium Phosphates Injection, USP (3 mmol/mL), must be diluted before use.

To avoid potassium or phosphate intoxication, infuse solutions containing potassium phosphates slowly. In patients with severe renal or adrenal insufficiency, administration of potassium phosphates may cause potassium intoxication, infusing high concentrations of phosphate may cause hypocalcemia, and calcium levels should be monitored.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 μg per kg per day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration of TPN products and of the lock-flush solutions used in their administration.

**PRECAUTIONS**

Phosphate replacement therapy with Potassium Phosphates Injection, USP should be guided primarily by the serum inorganic phosphate level and the limits imposed by the accompanying potassium (K⁺) ion.
High plasma concentrations of potassium may cause death through cardiac depression, arrhythmias or arrest.

Use with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.

**ADVERSE REACTIONS**

Adverse reactions involve the possibility of combined potassium and phosphate intoxication from overdosage. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heartblock, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest. Phosphate intoxication results in a reduction of serum calcium, and the symptoms are those of hypocalcemic tetany. See **WARNINGS**.

**OVERDOSAGE**

In the event of overdosage, discontinue infusions containing potassium phosphates immediately, and institute corrective therapy to restore depressed serum calcium and to reduce elevated serum potassium levels.

Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.

**DOSAGE AND ADMINISTRATION**

Potassium Phosphates Injection, USP (3 mmol/mL), is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage.

Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mmol) of phosphate and milliequivalents (mEq) of potassium (K⁺).

**AVAILABILITY OF DOSAGE FORMS**

<table>
<thead>
<tr>
<th>Product Number</th>
<th>Volume Fill</th>
<th>Vial Size</th>
<th>Phosphate/mL</th>
<th>Potassium/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>C8615P</td>
<td>15 mL</td>
<td>30 mL</td>
<td>285 mg</td>
<td>170 mg</td>
</tr>
<tr>
<td>C8650</td>
<td>50 mL</td>
<td>50 mL</td>
<td>285 mg</td>
<td>170 mg</td>
</tr>
</tbody>
</table>

The single-dose vials marked with “P” are partially filled. The products do not contain a bacteriostatic agent or other preservatives. They are packaged 25 vials per tray. Any unused portion should be discarded.

Store between 15 and 30°C.
Fresenius Kabi Canada Ltd.
45 Vogell Rd, Suite 200
Richmond Hill, ON L4B 3P6
☎ 1-877-821-7724

February 2015